Anti-CTLA-4 drugs, such as ipilimumab and tremelimumab, have not been approved in the treatment of patients with breast cancer, but there are many ongoing trials investigating the therapeutic role of ipilimumab in breast cancer. Here, CTLA4 is linked to breast cancer.